An interventional study of autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy in Erectile Dysfunction, sponsored by Taipei Medical University Hospital. Status unknown at 1 site in Taiwan. Open to male participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by Taipei Medical University Hospital · Not applicable, Interventional, and Treatment
The purpose of this clinical study is mainly to use platelet-rich plasma combined with low-intensity extracorporeal shockwave therapy to treat patients with erectile dysfunction and observe the improvement results.
According to statistics from the Taiwan Society of Andrology, 18 to 25 years old male population in Taiwan having erectile dysfunction (ED) trouble is as high as 5 to 10 percent. At the same time, statistics from the Taiwan Sexual Dysfunction Counseling Training Committee show that as many as 50 percent of men between 40 and 70 years old have erectile dysfunction. Erectile dysfunction is the most common sexual dysfunction in men and is believed to be related to nerve or blood vessel damage, and often significantly affects the patients' quality of life.
PRP is the abbreviation of "platelet-rich plasma". It can release growth factors and cytokines in the body to further promote tissue repair. The results of pre-clinical and clinical trials show that PRP can promote the repair of cavernous tissue, protect erection function of nerve, and stimulate the regeneration of nerve.
Low-intensity extracorporeal shockwave therapy (Li-ESWT) is a non-invasive treatment. Under this treatment, it will help body producing angiogenesis-related proteins, stimulating the formation of small blood vessels, generating new blood vessels at the site to be treated, and increasing the perfusion flow of local tissues. Li-ESWT has been clinically shown to have a significant effect on erectile dysfunction.
The purpose of this clinical study is mainly to use platelet-rich plasma combined with low-intensity extracorporeal shockwave therapy to treat patients with erectile dysfunction and observe the improvement results.
698 studies on the registry are indexed under Erectile Dysfunction; 116 are open to participants now.
This study's planned enrollment of 20 is below the median of 72 across 552 interventional studies indexed under Erectile Dysfunction.
Browse Erectile Dysfunction studies →Taipei Medical University Hospital is the lead sponsor of 64 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
Combination Product: autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy
The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria. 1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment. 2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment. 3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS. 4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment. 5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS. 6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS.
The Change in Erectile Function
Using the International Index of Erectile Function (IIEF) questionnaire.
Time frame: Baseline, the 4th week, 8th week, and 12th weeks
The Change in Erectile Function
Using the Erectile Hardness Scale (EHS) questionnaire to evaluate the efficacy of combined treatment of PRP and Li-ESWT
Time frame: Baseline, the 4th week, 8th week, and 12th weeks
Incidents of Side Effects
To observe whether there are side effects
Time frame: the 4th week, 8th week, and 12th weeks
Plan to share: No
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Medical University Hospital